Endocrine Abstracts

Introduction: Acromegaly is a rare, serious disease caused by the presence of a pituitary adenoma secreting an excessive amount of growth hormone (GH), which leads to a consequent increase in circulating insulin-like growth factor-1 (IGF-1) levels, and excessive skeletal growth and soft tissue enlargement. It is usually managed by surgery and/or treatment with somatostatin analogs (SSA). The ACRONIS study (CSOM230CIC05) will provide real-world evidence on the efficacy and safe...

Inactivating mutations of the calcium-sensing receptor (CaSR) gene, present in homozygous or heterozygous forms, cause neonatal severe hyperparathyroidism or familial hypocalciuric hypercalcemia. The R-568 binds to the transmembrane region of the CaSR thereby enhancing its sensitivity to extracellular calcium ([Ca2+]o) and inhibiting parathyroid hormone (PTH) secretion. The therapeutic potential of calcimimetics like R-568 has been demonstrated in patient...

Aim: The aim of this analysis was to determine whether low serum testosterone (T) and dehydroepiandrosterone sulfate (DHEAS) levels predict the development of metabolic syndrome (MetS) in men.Methods: Data were obtained from the Study of Health in Pomerania (SHIP), a population-based prospective cohort of adults aged 20–79 at baseline. Analyses were conducted in 1004 men without baseline MetS, defined by National Cholesterol Education Program Adult ...

Objective: Adiposity, insulin resistance, and hyperandrogenism are features of the polycystic ovary syndrome (PCOS). Retinol-binding protein 4 (RBP4) secreted from adipose and liver tissue has been linked to insulin resistance. We here address the impact of RBP4 on insulin resistance in PCOS and its usability to identify women with metabolic syndrome or impaired glucose metabolism (IGT or diabetes).Design: RBP4 was determined in plasma of 115 PCOS...

Introduction: Acromegalic patients (AP) often report fatigue and chronic subjective complaints. We aimed to investigate in more detail these aspects in AP, dependent on disease activity, age, gender, medication and pituitary insufficiency (PI).Patients/methods: Cross sectional, 124 patients (M/W 51/73, age 58.3±14.7 years, 49/75–active/controlled disease). The patients completed the Multidimensional Fatigue Inventory (MFI-20) and the Giessen Su...

Objectives: GH measurements during OGTT have profound effects on therapy and follow-up management of acromegaly. To minimize the discordance between immunoassays, it is recommended to calibrate them using 22 kDa-GH-preparation instead of the use of pituitary-derived calibrants. The aim of our study was to evaluate the between-method discrepancies in GH determinations by assays using different calibrants considering further confounders like age, gender, and BMI.<p class="ab...

Objective: The mechanisms underlying the well known glucagon-induced satiety effect are unclear. As we showed recently, the glucagon-induced reduction in total ghrelin, that might be responsible for this effect, is exerted at hypothalamus–pituitary level. The aim of the present study was to further evaluate glucagon’s suppressive effect on both total and acylated-ghrelin in obesity with respect to its role in appetite control.Methods: Prospecti...

Acromegaly is a morbid condition mainly caused by overproduction of growth-hormone (GH) from a pituitary adenoma leading to excessive growth. Normalisation of insulin-like growth factor-1 (IGF1) is an important goal for the treatment of acromegaly. The second-generation somatostatin analog (SSA) long acting pasireotide (la-PAS) has recently been introduced for the management of patients uncontrolled by first-generation SSA. The ACRONIS study (CSOM230CIC05) will provide real-wo...

Introduction: Heterozygous mutations in the AIP gene are associated with young-onset pituitary adenomas while homozygous loss of AIP in animal models is lethal. As early diagnosis could lead to better outcomes, family members of AIP mutation-positive patients need follow up. The R304Q variant is commonly described as pathogenic based on clinical assessment. However, it is also present in the general population (minor-allele-frequency (MAF) 0.0007&#15...